Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06621602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Study acronym: Syn-Q
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 11, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Apr 2026 to Apr 2027
    • Eligibility criteria revised
    • Site details revised at 18 of 18 sites
    v9
  2. Study sites: 17 to 18
    • Publications: details revised at 1 of 2 entries
    v8
  3. Study sites: 14 to 17
    • Publications: details revised at 1 of 2 entries
    v7
  4. Study sites: 13 to 14
    • Publications: details revised at 1 of 2 entries
    v6
  5. Study sites: 1 to 13
    • Publications: details revised at 1 of 2 entries
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date changed from estimate of Oct 2024 to Dec 17, 2024
    • Site contact updated
    v4
  2. Site contact updatedv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    • Publications: details revised at 1 of 2 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Trial Details
NCT Number NCT06621602
Lead Sponsor CND Life Sciences
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Conditions
(from sponsor)		 REM Behavior Disorder, Parkinson Disease
Related terms Parkinson Disease, REM Sleep Behavior Disorder
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov